Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MEMBRANEBLUE vs VISIONBLUE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Methylene blue (Membraneblue) is a selective inhibitor of guanylyl cyclase, thereby reducing cyclic guanosine monophosphate (c GMP) levels. It also acts as an electron carrier in the reduction of methemoglobin to hemoglobin.
Visionblue (trypan blue) is a dye that selectively stains the anterior lens capsule and vitreous, enhancing visualization during ophthalmic surgeries such as cataract extraction and vitrectomy. It does not exert pharmacological activity but acts as a vital stain.
Treatment of acquired methemoglobinemia,Diagnostic staining (e.g., parathyroid glands, lymphatic mapping),Off-label: Refractory vasoplegic shock, prevention of ifosfamide neurotoxicity
Staining of the anterior lens capsule during cataract surgery or capsulorhexis,Staining of vitreous in vitrectomy procedures
2 mg/kg intravenously once, administered over 30 minutes; may repeat once if clinically indicated after 30 minutes.
0.5 m L of 0.025% solution intracameral injection (single use).
Terminal elimination half-life 2.5-3.5 hours in adults; prolonged in hepatic or renal impairment (up to 6-8 hours).
Approximately 2.5 hours in patients with normal renal function; prolonged in renal impairment (up to 12 hours).
Reduced by NADPH-dependent methemoglobin reductase to leukomethylene blue; excreted in urine and bile.
Visionblue is not metabolized; it is cleared from the eye via aqueous humor outflow and systemic absorption is negligible.
Renal: approximately 60-70% unchanged; biliary/fecal: 20-30% as conjugated metabolites; minor pulmonary excretion.
Primarily eliminated unchanged via renal glomerular filtration; minimal biliary excretion (<5%).
Approximately 85-90% bound to albumin and alpha-1-acid glycoprotein.
Negligible (<5%), primarily to albumin.
0.35-0.45 L/kg, indicating primarily extracellular distribution.
0.2 L/kg, reflecting confinement to extracellular fluid and minimal tissue binding.
Intravenous: 100% (only route); oral bioavailability negligible (<1%) due to extensive first-pass metabolism.
Not applicable for systemic routes; intraocular administration yields direct local effect.
No specific dose adjustment recommended; use caution in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to limited data.
No dosage adjustment required; VISIONBLUE is not systemically absorbed.
No specific dose adjustment recommended; use with caution in severe hepatic impairment (Child-Pugh Class C) due to potential for altered metabolism.
No dosage adjustment required; VISIONBLUE is not systemically absorbed.
2 mg/kg intravenously once, not to exceed 100 mg total dose; repeat dosing not typically recommended.
Safety and efficacy not established in pediatric patients; no standard dosing available.
No specific dose adjustment required; monitor for renal function and fluid overload due to age-related physiological changes.
No specific adjustment; use adult dosing as indicated.
Serotonin syndrome with concurrent serotonergic drugs (especially SSRIs, SNRIs, MAOIs); discontinue serotonergic agents prior to use; do not use in patients taking serotonergic drugs.
None
Risk of serotonin syndrome when used with serotonergic agents; may cause severe hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency; may cause interferences with pulse oximetry readings; monitor methemoglobin levels; may cause fetal harm.
Intraocular use only; do not inject intravenously,Potential for corneal endothelial toxicity if excessive volume or prolonged contact,May cause transient increase in intraocular pressure,Hypersensitivity reactions have been reported,Use with caution in patients with compromised corneal endothelium
Known hypersensitivity to methylene blue; concurrent use with serotonergic drugs (SSRIs, SNRIs, MAOIs); severe G6PD deficiency.
Known hypersensitivity to trypan blue or any component of the formulation,Intraocular use in patients with significant corneal endothelial compromise
No known food interactions. Avoid alcohol consumption for 24 hours post-administration due to potential increased sedative effects.
No known food interactions. This drug is administered intraocularly and is not ingested; systemic absorption is negligible.
Current evidence indicates no increased risk of major congenital malformations with prenatal exposure. No known fetal risks during any trimester. However, human data are limited.
No teratogenic effects in animal studies; limited human data. Avoid use in pregnancy unless benefits outweigh risks.
Breastfeeding safety not established. M/P ratio unknown. Use caution during lactation due to potential for excretion.
Minimal systemic absorption; M/P ratio not reported. Compatible with breastfeeding but avoid direct infant eye contact.
No dose adjustment required based on pharmacokinetic changes during pregnancy.
No dosage adjustment needed; pharmacokinetics unchanged in pregnancy.
MEMBRANEBLUE (methylene blue) 1% solution is used intravenously for methemoglobinemia and as an optical imaging agent. Monitor for serotonergic toxicity if combined with SSRIs/SNRIs due to MAO inhibition. Do not exceed 7 mg/kg total dose to avoid severe adverse effects. Use with caution in G6PD deficiency due to risk of hemolytic anemia.
Vision Blue (trypan blue ophthalmic solution 0.06%) is a vital dye used as a surgical aid in cataract surgery for staining the anterior capsule during capsulorhexis. It selectively stains the anterior lens capsule due to its affinity for basement membranes, facilitating visualization in eyes with poor red reflex (e.g., white cataracts, dense brunescent cataracts). Avoid injecting into the vitreous; if encountered, perform anterior vitrectomy immediately. Use with caution in patients with pseudophakic or aphakic eyes due to risk of dye retention in the vitreous. Discard any unused solution after surgery; single-use vial only.
This medication may cause your urine, stool, or skin to turn blue-green, which is harmless and temporary.,Report any severe headache, chest pain, or difficulty breathing immediately.,Avoid taking medications for depression, anxiety, or migraine (SSRIs, SNRIs, MAOIs) within 24 hours of receiving MEMBRANEBLUE unless directed by your doctor.,If you have a history of glucose-6-phosphate dehydrogenase (G6PD) deficiency, inform your healthcare provider before treatment.
This medication is used during eye surgery to help your surgeon see the lens capsule clearly.,It is not self-administered; it will be applied by your surgeon during the procedure.,Inform your surgeon about any allergies, especially to dyes or medications.,Report any eye pain, redness, or vision changes after surgery immediately.,You may experience temporary blue discoloration of the eye, which resolves within days.
No interactions on record
No interactions on record
Common clinical questions about MEMBRANEBLUE vs VISIONBLUE, answered by our medical review team.
MEMBRANEBLUE is a Ophthalmic Dye that works by Methylene blue (Membraneblue) is a selective inhibitor of guanylyl cyclase, thereby reducing cyclic guanosine monophosphate (c GMP) levels. It also acts as an electron carrier in the reduction of methemoglobin to hemoglobin.. VISIONBLUE is a Ophthalmic Dye/Stain that works by Visionblue (trypan blue) is a dye that selectively stains the anterior lens capsule and vitreous, enhancing visualization during ophthalmic surgeries such as cataract extraction and vitrectomy. It does not exert pharmacological activity but acts as a vital stain.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MEMBRANEBLUE and VISIONBLUE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MEMBRANEBLUE is: 2 mg/kg intravenously once, administered over 30 minutes; may repeat once if clinically indicated after 30 minutes.. The standard adult dose of VISIONBLUE is: 0.5 m L of 0.025% solution intracameral injection (single use).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MEMBRANEBLUE and VISIONBLUE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MEMBRANEBLUE is classified as Category C. Current evidence indicates no increased risk of major congenital malformations with prenatal exposure. No known fetal risks during any trimester. However, human data are limited.. VISIONBLUE is classified as Category C. No teratogenic effects in animal studies; limited human data. Avoid use in pregnancy unless benefits outweigh risks.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.